The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension
Open accessAbstract
Pulmonary hypertension associated with increased pulmonary vascular resistance (PVR) and occurring in the setting of portal hypertension is referred to as “portopulmonary hypertension.” Intravenous epoprostenol (prostacyclin) is a potent pulmonary and systemic vasodilator with antithrombotic properties. It can decrease PVR and pulmonary artery pressure in patients with primary (idiopathic) pulmonary hypertension. Using right-heart catheterization, we evaluated the acute pulmonary hemodynamic effects of intravenous epoprostenol in patients with moderate to severe pulmonary hypertension (mean pulmonary artery pressure [MPAP] ≥35 mm Hg) associated with clinical manifestations of portal hypertension. Effects of long-term infusion of epoprostenol were also evaluated. We studied 15 consecutive patients with portopulmonary hypertension; 14 underwent acute administration of epoprostenol, and no significant side effects were noted. Ten patients received continuous epoprostenol (range, 8 days-30 months). Acute changes in PVR (−34% ± 18%), MPAP (−16% ± 10%), and cardiac output (CO) (+21 ± 18%), were statistically significant (P < .01). Long-term use of epoprostenol further lowered PVR (−47% ± 12% from baseline and −31% ± 22% from the acute change; P < .05) in the 6 patients restudied by right-heart catheterization. Death occurred in 6 of 10 (60%) of those receiving long-term epoprostenol. In moderate to severe portopulmonary hypertension, intravenous epoprostenol resulted in a significant improvement (both acute and long-term) in PVR, MPAP, and CO. Potential adverse effects on portal hypertension and implications for orthotopic liver transplantation (OLT), however, require further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Self-citationPrimary Pulmonary Hypertension: A National Prospective Study
RICH, S., DANTZKER, D. R., AYRES, S. M., BERGOFSKY, E. H., BRUNDAGE, B. H., DETRE, K. M., FISHMAN, A. P., GOLDRING, R. M., GROVES, B. M., KOERNER, S. K., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-216 · Cited by 2,039
McLaughlin, V. V., Genthner, D. E., Panella, M. M., & Rich, S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380501 · Cited by 664
Pulmonary vascular disorders in portal hypertension
Herve, P., Lebrec, D., Brenot, F., Simonneau, G., Humbert, M., Sitbon, O., & Duroux, P. (1998) · European Respiratory Journal · doi:10.1183/09031936.98.11051153 · Cited by 360
Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.
Rubin, L. J., Groves, B. M., Reeves, J. T., Frosolono, M., Handel, F., & Cato, A. E. (1982) · Circulation · doi:10.1161/01.cir.66.2.334 · Cited by 316
Robalino, B. D., & Moodie, D. S. (1991) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(10)80121-4 · Cited by 296
CONTINUOUS INTRAVENOUS INFUSION OF EPOPROSTENOL FOR THE TREATMENT OF PORTOPULMONARY HYPERTENSION1
Kuo, P. C., Johnson, L. B., Plotkin, J. S., Howell, C. D., Bartlett, S. T., & Rubin, L. J. (1997) · Transplantation · doi:10.1097/00007890-199702270-00020 · Cited by 234
Weir, E. K., Rubin, L. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Elliott, C. G., Fishman, A. P., Goldring, R. M., Groves, B. M., et al. (1989) · American Review of Respiratory Disease · doi:10.1164/ajrccm/140.6.1623 · Cited by 186
PULMONARY HYPERTENSION IN CHRONIC LIVER DISEASE
Mandell, M. S., & Groves, B. M. (1996) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(05)70296-3 · Cited by 163
Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin).
Jones, D. K., Higenbottam, T. W., & Wallwork, J. (1987) · Heart · doi:10.1136/hrt.57.3.270 · Cited by 161
Cited by
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 3,975
Authors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00879-2022 · Cited by 2,247
Metadata
- Authors
- Krowka, M. J., Frantz, R. P., McGoon, M. D., Severson, C., Plevak, D. J., & Wiesner, R. H.
- Venue
- Hepatology
- Published
- 1999-09
- Volume
- 30
- Issue
- 3
- Pages
- 641-648
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2150922388
- Cited by
- 292
- References
- 14
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. https://app.cochat.ai/papers/10.1002/hep.510300307
- The paper
- Krowka, M. J., Frantz, R. P., McGoon, M. D., Severson, C., Plevak, D. J., & Wiesner, R. H. (1999). Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology. https://doi.org/10.1002/hep.510300307
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.